Healthcare Value Capital’s AbbVie ABBV Stock Holding History

Healthcare Value Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-50,000	Closed	-$3.64M	–	23
2019 Q2	$3.64M	Buy	+50,000	New	+$3.93M	6.82%	5

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Healthcare Value Capital's ABBV Position: Q1 2021 in Review

Healthcare Value Capital sold out of AbbVie (ABBV) in Q1 2021, closing a stake of 35,000 shares — an estimated $3.75M sold.

Healthcare Value Capital first reported a position in ABBV in Q2 2015 and held it in 8 quarters. The position peaked at $4.43M in Q4 2019. 2,615 funds tracked by Wall St. Rank hold ABBV as of Q1 2021.

Healthcare Value Capital reported no remaining AbbVie position as of Q1 2021 after selling out during the quarter.
Healthcare Value Capital sold 35,000 AbbVie shares in Q1 2021, an estimated $3.75M.
Healthcare Value Capital first reported a position in AbbVie in Q2 2015 and held it in 8 quarters.
Healthcare Value Capital's AbbVie position peaked at $4.43M in Q4 2019.
2,615 funds tracked by Wall St. Rank held AbbVie as of Q1 2021.

Based on Healthcare Value Capital's 13F filing for Q1 2021, filed 17 May 2021.